{"id":48247,"date":"2024-07-27T17:50:01","date_gmt":"2024-07-27T17:50:01","guid":{"rendered":"https:\/\/i-base.info\/htb\/?p=48247"},"modified":"2024-07-31T11:53:22","modified_gmt":"2024-07-31T11:53:22","slug":"semaglutide-in-people-with-hiv-reduces-both-central-and-peripheral-fat-worsening-lipoatrophy","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/48247","title":{"rendered":"Semaglutide in people with HIV: reduces both central and peripheral fat worsening lipoatrophy"},"content":{"rendered":"<p><strong>Simon Collins, HIV i-Base<\/strong><\/p>\n<p><strong>Results from a phase 2 placebo-controlled clinical study of the GLP-1 agonist semaglutide in people with HIV-associated lipohypertrophy support the potential for reducing central fat but caution that it might also worsen peripheral lipoatrophy.<\/strong><\/p>\n<p>The study randomised 104 participants on effective ART with BMI &gt;25 kg\/m<sup>2<\/sup> and lipohypertrophy, but without diabetes, to once-weekly subcutaneous semaglutide or placebo for 32 weeks. Semaglutide was titrated for the first eight weeks and then given at 10 mg.<\/p>\n<p>The results included a 30% reduction in the primary outcome of changes in visceral abdominal adipose tissue (\u03b2 \u221230.82 cm<sup>2 <\/sup>[95% CI \u201350.13 to \u221211.51]).<\/p>\n<p>Reductions were also reported in abdominal subcutaneous adipose tissue (\u03b2 \u221242.01 cm<sup>2<\/sup>, [95% CI: \u221275.49 to \u22128.52] % change \u221211.2%) and total body fat (natural logarithmic \u22120\u00b721 kg [95% CI: \u22120\u00b733 to \u22120\u00b708] % change \u221218.9%).<\/p>\n<p dir=\"ltr\">Side effects were similar in each arm although one semaglutide-related grade 4 elevated lipase and two possibly related cases of cholelithiasis (grades 1 and 2) were observed.<\/p>\n<p dir=\"ltr\">8\/54 participants in each arm withdrew early.<\/p>\n<div dir=\"ltr\"><em>Note: This report is only compiled based on the published abstract and not the full paper.<\/em><\/div>\n<p dir=\"ltr\">Reference<\/p>\n<p dir=\"ltr\"><span>Ekhard AR et al. Once-weekly semaglutide in people with HIV-associated lipohypertrophy: a randomised, double-blind, placebo-controlled phase 2b single-centre clinical trial. Lancet Diabetes and Endocrinology.\u00a0<\/span><span class=\"article-header__doi__label\">DOI: <\/span><span>10.1016\/S2213-8587(24)00150-5. (01<\/span><span class=\"article-header__publish-date bulleted\"><span class=\"article-header__publish-date__value\">July 2024).<\/span><\/span><\/p>\n<div dir=\"ltr\">\n<p class=\"article-header__title smaller\"><a href=\"https:\/\/www.thelancet.com\/journals\/landia\/article\/PIIS2213-8587(24)00150-5\/abstract\">https:\/\/www.thelancet.com\/journals\/landia\/article\/PIIS2213-8587(24)00150-5\/abstract<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Simon Collins, HIV i-Base Results from a phase 2 placebo-controlled clinical study of the GLP-1 agonist semaglutide in people with HIV-associated lipohypertrophy support the potential for reducing central fat but caution that it might also worsen peripheral lipoatrophy. The study &hellip;<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[8,27],"tags":[],"class_list":["post-48247","post","type-post","status-publish","format-standard","hentry","category-side-effects","category-weight-diabetes-metabolic-complications"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/48247","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=48247"}],"version-history":[{"count":15,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/48247\/revisions"}],"predecessor-version":[{"id":48326,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/48247\/revisions\/48326"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=48247"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=48247"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=48247"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}